April 18 (Reuters) - French drugmaker Sanofi

said on Thursday it would restructure the U.S. com­mer­cial

op­er­a­tions for its vac­cines and cut an undis­closed num­ber

of jobs.

Sanofi would implement a "stream­lined strate­gic sales

struc­ture" to better support its customers and patients, it

said without disclosing any details on the changes to be made,

the time­frame and the num­ber of em­ploy­ees to be im­pact­ed.

Endpoints News first reported the development on Thursday.

Sanofi CEO Paul Hudson has been trying to build investor

confidence in the company's drug pipeline since he unexpectedly

abandoned 2025 margin targets last October to instead boost drug

development spending.

The company's vaccine portfolio includes preventive shots

for a common respiratory infection in infants, influenza

vaccines, COVID vaccines and vaccines for infections like

meningitis and tetanus.